Research ExplorerPublicationsA phase II trial of weekly irinotecan in cisplatin-refractor...

A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer.

Standard

A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. / Burkart, Christof; Bokemeyer, Carsten; Klump, Bodo; Pereira, Philippe; Teichmann, Reinhard; Hartmann, Jörg Thomas.

In: ANTICANCER RES, Vol. 27, No. 4, 4, 2007, p. 2845-2848.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Burkart, C, Bokemeyer, C, Klump, B, Pereira, P, Teichmann, R & Hartmann, JT 2007, 'A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer.', ANTICANCER RES, vol. 27, no. 4, 4, pp. 2845-2848. <http://www.ncbi.nlm.nih.gov/pubmed/17695458?dopt=Citation>

APA

Burkart, C., Bokemeyer, C., Klump, B., Pereira, P., Teichmann, R., & Hartmann, J. T. (2007). A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. ANTICANCER RES, 27(4), 2845-2848. [4]. http://www.ncbi.nlm.nih.gov/pubmed/17695458?dopt=Citation

Vancouver

Burkart C, Bokemeyer C, Klump B, Pereira P, Teichmann R, Hartmann JT. A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. ANTICANCER RES. 2007;27(4):2845-2848. 4.

Bibtex

@article{6a60002f51b74a678af65e68de49f9b1,
title = "A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer.",
abstract = "BACKGROUND: This study investigated the efficacy and toxicity of weekly single-agent irinotecan in patients with metastatic disease relapsing after cisplatin-based chemotherapy. PATIENTS AND METHODS: Fourteen patients were enrolled. A total number of 29 cycles (one cycle consisted of CPT-11 100 mg/m2 on days 1, 8, 15, qd 28) were applied. Irinotecan was continued until disease progression or unacceptable toxicity occurred. Where toxicity was less than WHO grade 3, the dose of irinotecan was escalated in 20 mg steps in subsequent cycles up to a maximum dose of 140 mg/m2. Patients were assessed for response according to WHO criteria every second cycle. RESULTS: Of the 13 evaluable patients, 2 achieved a partial response (PR) and 3 disease stabilisation (NC); progressive disease (PD) was noted in 8 patients. Median time to progression was 2 months (range: 1-8 months) and median survival from start of study treatment was 5 months (range: 2-16 months). Grade 3 toxicity consisted of diarrhea (n=3), fever (n=1) and pain (n=1). CONCLUSION: Single-agent irinotecan has moderate activity in cisplatin-refractory esophageal cancer.",
author = "Christof Burkart and Carsten Bokemeyer and Bodo Klump and Philippe Pereira and Reinhard Teichmann and Hartmann, {J{\"o}rg Thomas}",
year = "2007",
language = "Deutsch",
volume = "27",
pages = "2845--2848",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

RIS

TY - JOUR

T1 - A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer.

AU - Burkart, Christof

AU - Bokemeyer, Carsten

AU - Klump, Bodo

AU - Pereira, Philippe

AU - Teichmann, Reinhard

AU - Hartmann, Jörg Thomas

PY - 2007

Y1 - 2007

N2 - BACKGROUND: This study investigated the efficacy and toxicity of weekly single-agent irinotecan in patients with metastatic disease relapsing after cisplatin-based chemotherapy. PATIENTS AND METHODS: Fourteen patients were enrolled. A total number of 29 cycles (one cycle consisted of CPT-11 100 mg/m2 on days 1, 8, 15, qd 28) were applied. Irinotecan was continued until disease progression or unacceptable toxicity occurred. Where toxicity was less than WHO grade 3, the dose of irinotecan was escalated in 20 mg steps in subsequent cycles up to a maximum dose of 140 mg/m2. Patients were assessed for response according to WHO criteria every second cycle. RESULTS: Of the 13 evaluable patients, 2 achieved a partial response (PR) and 3 disease stabilisation (NC); progressive disease (PD) was noted in 8 patients. Median time to progression was 2 months (range: 1-8 months) and median survival from start of study treatment was 5 months (range: 2-16 months). Grade 3 toxicity consisted of diarrhea (n=3), fever (n=1) and pain (n=1). CONCLUSION: Single-agent irinotecan has moderate activity in cisplatin-refractory esophageal cancer.

AB - BACKGROUND: This study investigated the efficacy and toxicity of weekly single-agent irinotecan in patients with metastatic disease relapsing after cisplatin-based chemotherapy. PATIENTS AND METHODS: Fourteen patients were enrolled. A total number of 29 cycles (one cycle consisted of CPT-11 100 mg/m2 on days 1, 8, 15, qd 28) were applied. Irinotecan was continued until disease progression or unacceptable toxicity occurred. Where toxicity was less than WHO grade 3, the dose of irinotecan was escalated in 20 mg steps in subsequent cycles up to a maximum dose of 140 mg/m2. Patients were assessed for response according to WHO criteria every second cycle. RESULTS: Of the 13 evaluable patients, 2 achieved a partial response (PR) and 3 disease stabilisation (NC); progressive disease (PD) was noted in 8 patients. Median time to progression was 2 months (range: 1-8 months) and median survival from start of study treatment was 5 months (range: 2-16 months). Grade 3 toxicity consisted of diarrhea (n=3), fever (n=1) and pain (n=1). CONCLUSION: Single-agent irinotecan has moderate activity in cisplatin-refractory esophageal cancer.

M3 - SCORING: Zeitschriftenaufsatz

VL - 27

SP - 2845

EP - 2848

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 4

M1 - 4

ER -